It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Early identification of high-risk metabolic dysfunction-associated steatohepatitis (MASH) can offer patients access to novel therapeutic options and potentially decrease the risk of progression to cirrhosis. This study aimed to develop an explainable machine learning model for high-risk MASH prediction and compare its performance with well-established biomarkers. Data were derived from the National Health and Nutrition Examination Surveys (NHANES) 2017-March 2020, which included a total of 5281 adults with valid elastography measurements. We used a FAST score ≥ 0.35, calculated using liver stiffness measurement and controlled attenuation parameter values and aspartate aminotransferase levels, to identify individuals with high-risk MASH. We developed an ensemble-based machine learning XGBoost model to detect high-risk MASH and explored the model’s interpretability using an explainable artificial intelligence SHAP method. The prevalence of high-risk MASH was 6.9%. Our XGBoost model achieved a high level of sensitivity (0.82), specificity (0.91), accuracy (0.90), and AUC (0.95) for identifying high-risk MASH. Our model demonstrated a superior ability to predict high-risk MASH vs. FIB-4, APRI, BARD, and MASLD fibrosis scores (AUC of 0.95 vs. 0.50, 0.50, 0.49 and 0.50, respectively). To explain the high performance of our model, we found that the top 5 predictors of high-risk MASH were ALT, GGT, platelet count, waist circumference, and age. We used an explainable ML approach to develop a clinically applicable model that outperforms commonly used clinical risk indices and could increase the identification of high-risk MASH patients in resource-limited settings.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Yale School of Medicine, Section of Digestive Diseases, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Harvard Medical School, Global Clinical Scholars Research Program, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); University of Oxford Said Business School, Artificial Intelligence Programme, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
2 University of Texas Health San Antonio, San Antonio, USA (GRID:grid.215352.2) (ISNI:0000 0001 2184 5633)
3 Centers for Medicare and Medicaid Services, Baltimore, USA (GRID:grid.413874.d) (ISNI:0000 0001 2300 5144)
4 New York Medical College, School of Medicine, Valhalla, USA (GRID:grid.260917.b) (ISNI:0000 0001 0728 151X)
5 Yale School of Medicine, Section of Digestive Diseases, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)




